North Carolina life science companies hauled in more than $1.1 billion worth of investments and grant money in the last year, according to a report from the North Carolina Biosciences Organization.NCBIO, a Durham, North Carolina-based trade group, presented the figures to state legislators at a briefing for North Carolina lawmakers. The group conducts the survey [...]

Updated 6:47 p.m.Small molecule discovery and development company Akebia Therapeutics Inc. reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting the round to $17 million.var page_count = “off”; [...]

Radiopharmaceuticals company Cellectar Inc. has enrolled the last of eight patients in a Phase 1 trial of its cancer-treating drug candidate.The trial is designed to measure drug safety and dosimetry of Cellectar’s lead compound, called CLR1404. Dosimetry refers to the measurement of doses, which also allows investigators to understand how a drug will affect non-tumor [...]

Cellectar Inc. has raised $2.7 million for its radiopharmaceutical technology that treats and detects a variety of cancers, according to a regulatory filing. The company’s lead compound is currently in Phase 1 clinical trials for cancer treatment.

The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems — a side effect of some cancer treatments.